ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.703,82
0,37%
S&P 500
5.495,21
0,15%
US Dollar vs BRL
5,4373
0,25%
Bitcoin
64.819,92
-0,23%
Brent Oil
85,085
0,46%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Monopar Therapeutics Inc (MNPR)

  7. Monopar Therapeutics Inc (MNPR) Notícias

MNPR

Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MNPR
DataHoraFonteTítuloCódigoCompanhia
17/06/202419:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
11/06/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
11/06/202408:30GlobeNewswire Inc.Monopar and NorthStar Amend & Extend CollaborationNASDAQ:MNPRMonopar Therapeutics Inc
10/06/202409:00GlobeNewswire Inc.Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
24/05/202409:00GlobeNewswire Inc.Monopar Announces CFO SuccessionNASDAQ:MNPRMonopar Therapeutics Inc
09/05/202408:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
09/05/202408:00GlobeNewswire Inc.Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineNASDAQ:MNPRMonopar Therapeutics Inc
18/04/202409:00GlobeNewswire Inc.Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
16/04/202409:00GlobeNewswire Inc.Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsNASDAQ:MNPRMonopar Therapeutics Inc
10/04/202409:00GlobeNewswire Inc.Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsNASDAQ:MNPRMonopar Therapeutics Inc
28/03/202408:00GlobeNewswire Inc.Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
05/03/202409:00GlobeNewswire Inc.Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramNASDAQ:MNPRMonopar Therapeutics Inc
27/02/202409:00GlobeNewswire Inc.Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialNASDAQ:MNPRMonopar Therapeutics Inc
22/02/202409:00GlobeNewswire Inc.Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
20/02/202410:00GlobeNewswire Inc.Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
09/11/202309:00GlobeNewswire Inc.Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
01/11/202308:00GlobeNewswire Inc.Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
10/10/202308:00GlobeNewswire Inc.Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
05/09/202308:00GlobeNewswire Inc.Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
10/08/202308:00GlobeNewswire Inc.Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
08/08/202308:00GlobeNewswire Inc.Monopar Provides Encouraging Camsirubicin Clinical Data UpdateNASDAQ:MNPRMonopar Therapeutics Inc
11/07/202308:00GlobeNewswire Inc.Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeNASDAQ:MNPRMonopar Therapeutics Inc
28/06/202317:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MNPRMonopar Therapeutics Inc
21/06/202308:00GlobeNewswire Inc.Monopar to Participate in the Radiopharma Forum by the Lake 2023NASDAQ:MNPRMonopar Therapeutics Inc
14/06/202308:00GlobeNewswire Inc.Monopar to Participate in the Maxim Group’s Healthcare Virtual ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
02/06/202317:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:MNPRMonopar Therapeutics Inc
01/06/202308:00GlobeNewswire Inc.Monopar Announces Encouraging Camsirubicin Phase 1b Trial UpdateNASDAQ:MNPRMonopar Therapeutics Inc
11/05/202308:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MNPRMonopar Therapeutics Inc
11/05/202308:00GlobeNewswire Inc.Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
28/04/202317:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MNPRMonopar Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MNPR

Seu Histórico Recente

LBNK
DALIUSDT
DALICHAIN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados